BridgeMD
Midazolam and morphine to alleviate symptoms at the end of life in patients on acute geriatric wards
EU CTIS ID: 2024-517763-22-00
What this study is testing
1. To characterize the relationship between morphine dosing and the time to symptom control (discomfort/pain and dyspnea) in geriatric patients during their last days of life. 2. To characterize the relationship between midazolam dosing and the time to symptom control (discomfort/pain, dyspnea and agitation) in geriatric patients during their last days of life. 3. To characterize the relationship between morphine dosage and the occurrence of adverse drug reactions in geriatric patients during their last days of life. 4. To characterize the relationship between midazolam dosage and the occurrence of adverse drug reactions in geriatric patients during their last days of life.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Hospitalization on the acute geriatric ward
- Patient expected to die in the following hours or days
You likely can't join if
- Expected discharge from the hospital before death
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.